Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Silo Pharma (SILO) Non Operating Investment Income (2021 - 2023)

Silo Pharma's Non Operating Investment Income history spans 3 years, with the latest figure at -$3508.0 for Q2 2023.

  • For Q2 2023, Non Operating Investment Income rose 96.65% year-over-year to -$3508.0; the TTM value through Dec 2023 reached -$3118.0, up 98.83%, while the annual FY2023 figure was -$3118.0, 97.02% up from the prior year.
  • Non Operating Investment Income for Q2 2023 was -$3508.0 at Silo Pharma, down from $390.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $151682.0 in Q4 2022 and bottomed at -$161798.0 in Q1 2022.
  • The 3-year median for Non Operating Investment Income is -$3508.0 (2023), against an average of -$37750.4.
  • The largest annual shift saw Non Operating Investment Income surged 2728.31% in 2022 before it soared 96.65% in 2023.
  • A 3-year view of Non Operating Investment Income shows it stood at $5363.0 in 2021, then soared by 2728.31% to $151682.0 in 2022, then crashed by 102.31% to -$3508.0 in 2023.
  • Per Business Quant, the three most recent readings for SILO's Non Operating Investment Income are -$3508.0 (Q2 2023), $390.0 (Q1 2023), and $151682.0 (Q4 2022).